ClinicaliQ Trial Snapshot
- A Phase IIb Study to Evaluate AZD8965 in Participants With IPF. — Recruiting • Phase II • Respiratory / COPD / Asthma • NCT07652658.
- Treatment being tested: AZD8965 at three different doses versus placebo in patients with idiopathic pulmonary fibrosis (IPF), assessed for efficacy, safety, and tolerability, with potential use alongside existing antifibrotic therapies (nintedanib, pirfenidone, nerandomilast).
- Patient eligibility overview: Adults with confirmed IPF diagnosis, including those currently receiving antifibrotic monotherapy or combination therapy, or treatment-Phase IIïve patients, meeting specified baseline lung function and disease severity criteria.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This Phase IIb study aims to evaluate the efficacy, safety, and tolerability of 3 doses of AZD8965 treatment compared to placebo in participants with IPF, including those on antifibrotic therapy (nintedanib, pirfenidone, nerandomilast), either alone or in combination, or in those not on antifibrotic therapy.
Eligibility Snapshot
- : 1. Age ≥ 40 years 2. IPF diagnosis
- Participants with IPF receiving locally approved antifibrotic therapies at a stable dose, or participants with IPF not receiving local standard of care 4. FVC ≥ 45% predicted of normal 5. DLCO corrected for hemoglobin ≥ 25% predicted of normal
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.